Skip to main content
SpringerLink
Log in

TNFi cycling more costly than switching MOA in RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chastek B, et al. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. Advances in Therapy : 16 Oct 2017. Available from: URL: http://doi.org/10.1007/s12325-017-0617-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

TNFi cycling more costly than switching MOA in RA. PharmacoEcon Outcomes News 790, 33 (2017). https://doi.org/10.1007/s40274-017-4478-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4478-6

Search

Navigation